Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 148 No. 5152 (2018)

Hepatic manifestations of Wilson’s disease: 12-year experience in a Swiss tertiary referral centre

  • Joana Vieira Barbosa
  • Montserrat Fraga
  • Joan Saldarriaga
  • Philippe Hiroz
  • Emiliano Giostra
  • Christine Sempoux
  • Peter Ferenci
  • Darius Moradpour
DOI
https://doi.org/10.4414/smw.2018.14699
Cite this as:
Swiss Med Wkly. 2018;148:w14699
Published
30.12.2018

Summary

BACKGROUND AND AIM

Wilson’s disease is an inherited disorder of hepatic copper metabolism, leading to the accumulation of copper in the liver as well as the brain, cornea and other organs. Here, we describe the adult cases of hepatic Wilson’s disease diagnosed at the Division of Gastroenterology and Hepatology of the University Hospital Lausanne, Switzerland between September 2004 and August 2016.

METHODS

Clinical manifestations, results of diagnostic tests, management and outcomes of adult patients with hepatic Wilson’s disease were assessed based on standardised medical records. In addition, liver histology was reviewed and the lesional patterns were recorded.

RESULTS

Ten new adult cases of hepatic Wilson’s disease were diagnosed in our centre between September 2004 and August 2016. Male to female ratio was 1:1 and median age at diagnosis was 26 (range 18–56) years. Four patients presented with acute liver failure, four with persistently elevated liver function tests, and two with decompensated cirrhosis; none had neurological manifestations. Only one patient had a Kayser-Fleischer corneal ring. Median ceruloplasmin level at diagnosis was 0.13 (range <0.03–0.30) g/l, median 24-hour urinary copper excretion was 2.8 (range 0.3–77.3) μmol, and median hepatic copper concentration was 789 (range 284–1677) μg/g. At least one mutation in the ATP7B gene was identified in eight patients. Allelic frequency of the common H1069Q mutation was 19%. Leipzig score was ≥5 in all patients. Three patients presenting with acute liver failure and the two with decompensated cirrhosis underwent successful liver transplantation. One patient with acute liver failure recovered under chelation therapy, as predicted by a Dhawan score <11. D-penicillamine was used as first-line chelator treatment, with a subsequent switch to trientine due to adverse effects in three out of six patients.

CONCLUSIONS

The clinical presentation of hepatic Wilson’s disease is highly variable. Three out of 10 patients were diagnosed at an age >35 years. A high index of suspicion in clinically compatible situations is key.

References

  1. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–85. doi:.https://doi.org/10.1016/j.jhep.2011.11.007
  2. Roberts EA, Schilsky ML ; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089–111. doi:.https://doi.org/10.1002/hep.22261
  3. Gitlin JD. Wilson disease. Gastroenterology. 2003;125(6):1868–77. doi:.https://doi.org/10.1053/j.gastro.2003.05.010
  4. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet. 2007;369(9559):397–408. doi:.https://doi.org/10.1016/S0140-6736(07)60196-2
  5. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, et al. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology. 1997;113(1):212–8. doi:.https://doi.org/10.1016/S0016-5085(97)70097-0
  6. Stromeyer FW, Kamal GI, Gerber MA, Mathew T. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. 1980;74(3):254–8. doi:.https://doi.org/10.1093/ajcp/74.3.254
  7. Johncilla M, Mitchell KA. Pathology of the liver in copper overload. Semin Liver Dis. 2011;31(3):239–44. doi:.https://doi.org/10.1055/s-0031-1286055
  8. Schilsky ML. Wilson disease: Diagnosis, treatment, and follow-up. Clin Liver Dis. 2017;21(4):755–67. doi:.https://doi.org/10.1016/j.cld.2017.06.011
  9. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139–42. doi:.https://doi.org/10.1034/j.1600-0676.2003.00824.x
  10. Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11(4):441–8. doi:.https://doi.org/10.1002/lt.20352
  11. Maier-Dobersberger T, Ferenci P, Polli C, Balać P, Dienes HP, Kaserer K, et al. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med. 1997;127(1):21–6. doi:.https://doi.org/10.7326/0003-4819-127-1-199707010-00004
  12. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet. 1995;9(2):210–7. doi:. Erratum in: Nat Genet. 1995;9:451.https://doi.org/10.1038/ng0295-210
  13. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology. 2005;41(3):668–70. doi:.https://doi.org/10.1002/hep.20601
  14. Ferenci P, Członkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, et al. Late-onset Wilson’s disease. Gastroenterology. 2007;132(4):1294–8. doi:.https://doi.org/10.1053/j.gastro.2007.02.057
  15. Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson’s disease: an experience over three decades. Gut. 2000;46(3):415–9. doi:.https://doi.org/10.1136/gut.46.3.415
  16. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut. 2007;56(1):115–20. doi:.https://doi.org/10.1136/gut.2005.087262
  17. Ferenci P. Phenotype-genotype correlations in patients with Wilson’s disease. Ann N Y Acad Sci. 2014;1315(1):1–5. doi:.https://doi.org/10.1111/nyas.12340
  18. O’Brien A, Williams R. Rapid diagnosis of Wilson disease in acute liver failure: no more waiting for the ceruloplasmin level? Hepatology. 2008;48(4):1030–2. doi:.https://doi.org/10.1002/hep.22587
  19. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH, Jr, et al.; Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008;48(4):1167–74. doi:.https://doi.org/10.1002/hep.22446
  20. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet. 2006;120(2):151–9. doi:.https://doi.org/10.1007/s00439-006-0202-5
  21. Bruha R, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int. 2011;31(1):83–91. doi:.https://doi.org/10.1111/j.1478-3231.2010.02354.x
  22. Ferenci P. Wilson’s Disease. Clin Gastroenterol Hepatol. 2005;3(8):726–33. doi:.https://doi.org/10.1016/S1542-3565(05)00484-2
  23. Gupta A, Das S, Ray K. A glimpse into the regulation of the Wilson disease protein, ATP7B, sheds light on the complexity of mammalian apical trafficking pathways. Metallomics. 2018;10(3):378–87. doi:.https://doi.org/10.1039/C7MT00314E
  24. Medici V, Trevisan CP, D’Incà R, Barollo M, Zancan L, Fagiuoli S, et al. Diagnosis and management of Wilson’s disease: results of a single center experience. J Clin Gastroenterol. 2006;40(10):936–41. doi:.https://doi.org/10.1097/01.mcg.0000225670.91722.59

Most read articles by the same author(s)